Showing 6991-7000 of 8194 results for "".
- Lead Pharma Begins Phase I Trials with SAR441169 Candidate Treatment for Psoriasishttps://practicaldermatology.com/news/lead-pharma-to-begin-phase-i-trials-with-sar441169-candidate-treatment-for-psoriasis/2459962/Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of immunological and oncological indications, achieved a fourth milestone under its license & collaboration agreement with Sanofi, triggering an undisclosed milestone payment. The milestone payment is link
- Cutera Hosts Beauty Talk with Sadick and Sadickhttps://practicaldermatology.com/news/cuter-hosts-beauty-talk-with-sadick-and-sadick/2459960/Dermatologist Neil Sadick, MD and his daughter Sydney Sadick, an in-the-know fashion journalist, talked about everything from state-of-the-art skin brightening treatments to the newest injectables and how to get svelte without sweating or surgery at
- Jean Bolognia, MD Honored with AAD Gold Medalhttps://practicaldermatology.com/news/jean-bolognia-md-honored-with-aad-gold-medal/2459966/During the 2019 Annual Meeting of the American Academy of Dermatology (AAD) in Washington, D.C., the AAD awarded Jean Bolognia, MD, Professor of Dermatology at the Yale University School of Medicine, with its Gol
- AAD Announces 2019 Election Resultshttps://practicaldermatology.com/news/aad-announces-2019-election-results/2459967/The votes have been counted in the 2019 AAD Election, and the following candidates will take office at the conclusion of the 2020 Annual Meeting in Denver, Colorado on March 24, 2020.
- Galderma Collaborates with Nespresso to Offer Patient Loyalty Incentive Programhttps://practicaldermatology.com/news/galderma-collaborates-with-nespresso-to-offer-patient-loyalty-incentive-program/2459968/Galderma Laboratories, L.P., recently teamed up with Nespresso to offer a new rewards program for patients who seek Restylane treatments from aesthetic professionals. With a qualifying purchase of Restylane dermal fillers, aesthetic professionals will receive a set of vouchers for complimentary N
- 2019 NewBeauty Awards: Alastin's TransFORM Body Treatment Acknowledged for Innovationhttps://practicaldermatology.com/news/2019-newbeauty-awards-alastins-transform-body-treatment-acknowledged-for-innovation/2459977/ALASTIN Skincare, Inc’s TransFORM Body Treatment has been awarded a 2019 NewBeauty Award in the innovations category. NewBeauty acknowledges the best products, treatments and trends in cosmetics and aesthetics with their innovation category described as, "the future is now
- New Mouse Model Validates How “Good” and “Bad” Bacteria Affect Acnehttps://practicaldermatology.com/news/new-mouse-model-validates-how-good-and-bad-bacteria-affect-acne/2459981/Researchers at University of California San Diego School of Medicine, Cedars-Sinai and UCLA have developed a new mouse model that closely resembles human acne by adding one new factor — a synthetic sebum. Researchers have long believed that Propionibacterium acnes causes ac
- New HelloBello Baby Care Products Make a Big Splash at Walmarthttps://practicaldermatology.com/news/new-hellobello-baby-care-products-make-a-big-splash-at-walmart/2459983/Walmart is rolling out a host of new products from HelloBello, an affordable plant-based baby care line co-founded by Kristen Bell and Dax Shepard. Hello Bello will launch with 10 products including diapers, wipes, shampoo & body wash, bubb
- Pulse Biosciences, Inc's CellFX System Performs Well in Sebaceous Hyperplasia Studyhttps://practicaldermatology.com/news/pulse-biosciences-incs-cellfx-system-performs-well-in-sebaceous-hyperplasia-study/2459987/Pulse Biosciences, Inc’s CellFX Nano-Pulse Stimulation system cleared more than 90 percent of sebaceous hyperplasia (SH) lesions in a study presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington, DC.
- Bimekizumab Provides Long-Term Skin Clearance for Psoriasis Patients in Phase 2b Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-extension-study/2459873/UCB’s bimekizumab demonstrated long-term maintenance of complete or almost complete skin disease resolution for psoriasis patients, according to results from the Phase 2b BE ABLE 2 Extension Study presented at the 2019 American Academy of Dermatology Annual Meeting (AAD) in Washington,